EyePoint Pharmaceuticals (EYPT)
(Delayed Data from NSDQ)
$12.94 USD
+0.49 (3.94%)
Updated May 15, 2024 04:00 PM ET
After-Market: $12.92 -0.02 (-0.15%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$12.94 USD
+0.49 (3.94%)
Updated May 15, 2024 04:00 PM ET
After-Market: $12.92 -0.02 (-0.15%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Zacks News
EyePoint Pharmaceuticals (EYPT) Soars 21.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EyePoint Pharmaceuticals (EYPT) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
GSK to Boost Vaccine Portfolio With Affinivax Acquisition
by Zacks Equity Research
GSK signs an agreement to acquire Affinivax, Inc. for a $2.1 billion upfront payment. The company is looking to boost its vaccine pipeline with this acquisition.
AbbVie (ABBV) Files NDA for Parkinson's Disease Candidate
by Zacks Equity Research
AbbVie (ABBV) submits a new drug application to the FDA for ABBV-951, which has been developed for treating advanced Parkinson's disease.
Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.
Horizon (HZNP) Begins Enrollment in Alopecia Areata Study
by Zacks Equity Research
Horizon (HZNP) enrolls the first patient in a phase II study evaluating daxdilimab (HZN-7734) for the treatment of alopecia areata.
Seagen's (SGEN) Stock Up on CEO's Resignation Announcement
by Zacks Equity Research
Seagen's (SGEN) current chief executive officer and president, Clay Siegall, announces his resignation. The company is looking for a new CEO. Stock up.
Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta Thalassemia
by Zacks Equity Research
The FDA bestows an Orphan Drug designation to Editas' (EDIT) investigational gene therapy, EDIT-301, for treating beta thalassemia. Shares up in after-hours trading.
Down 18.2% in 4 Weeks, Here's Why You Should You Buy the Dip in EyePoint Pharmaceuticals (EYPT)
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -4% and 10.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -18% and 14.72%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 0% and 0.89%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -23.40% and -5.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alcon, National Vision, The Cooper Companies and EyePoint Pharma
4 Stocks to Keep a Watch on Amid Growing Optical Care Demand
by Riya Anand
Stocks like Alcon (ALC), National Vision (EYE), The Cooper Companies (COO) and EyePoint Pharmaceuticals (EYPT) are gaining momentum amid rising optical care demand.
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 22.22% and 2.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 5.66% and -11.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -324.44% and -70.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Stamps.com, Ribbon Communications, American Software and EyePoint Pharmaceuticals
by Zacks Equity Research
Zacks.com featured highlights include: Stamps.com, Ribbon Communications, American Software and EyePoint Pharmaceuticals
4 Stocks in the Limelight on New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Stamps.com Inc. (STMP), Ribbon Communications Inc. (RBBN), American Software, Inc. (AMSWA) and EyePoint Pharmaceuticals, Inc. (EYPT).
Will Walgreens Boots' (WBA) Retail Arm Be Dull in Q1 Earnings?
by Zacks Equity Research
Walgreens Boots' (WBA) retail pharmacy international sales are likely to remain dull in Q1 on difficult market scenario in the United Kingdom.
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -200.00% and 0.22%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals (EYPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
EyePoint Pharmaceuticals (EYPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.